The aim of the study was to compare effects of selective beta-1-adrenoblocker metoprolol (corvitol), clophelin (clonidine) and dopegyt (methyldopa) on mother's hemodynamics and feto-placental complex state. In total, 60 pregnant women with Stage II essential arterial hypertension (AH), and 20 healthy pregnant women of similar age and gestation duration, were examined. The patients were divided into three clinical groups: Group I received metoprolol (50 mg twice per day; after blood pressure (BP) stabilization - 25 mg/d), Group II - clophelin (0, 075 mg 2-3 times per day), Group III - dopegyt (250 mg twice per day). Treatment effectiveness was assessed by mother's echocardiography, feto-placental vessel dopplerometry, fetal cardiotocography, placental histology. In hypertensive women with hyperkinetic hemodynamics, metoprolol more effectively, than clophelin and dopegyt, reduced BP, normalized mother's central hemodynamics, restored feto-placental blood flow, and increased fetal cardiovascular system reactivity. Clophelin was clinically effective in patients with hypokinetic central hemodynamics, dopegyt - in women with eukinetic hemodynamics. Antihypertensive therapy in pregnant women with essential AH should be differential, according to central hemodynamics type.

In 126 patients with coronary heart disease (CHD), complex assessment of lipid peroxidation (LP) and antioxidant protection, blood rheology, and their interaction with clinical and hemodynamical parameters, was performed. According to correlation analysis, CHD patients demonstrated associations between LP parameters, antioxidant enzyme levels and antioxidants of plasma anti-radical pool. PL parameters correlated with red blood cell and platelet functional activity. Regulatory role of antioxidant system (AOS) in lipid peroxidation metabolism and peroxide blood cell damage in CHD was demonstrated. Associations between PL, AOS, and hemorheology parameters were detected, confirming pathogenetic role of these disturbances in CHD pathogenesis.

The authors studied effects of short-term (8 weeks) combined lipid-lowering and antihypertensive therapy effects on hemostatic parameters in metabolic syndrome (MS) patients. The treatment with fibrates and antihypertensive medications was associated with fibrinogen level reduction (for combination of fenofibrate and atenolol). Statin therapy was associated with fibrinogen level decrease (lovastatin plus perindopril) and fibrinolysis activation (simvastatin plus indapamide). Possible pleiotropic mechanisms of lipid-lowering and antihypertensive medications could beneficially influence hemostasis system.

The authors propose a prognostic model for assessing death risk in patients hospitalized with acute coronary syndrome (possible myocardial infarction or unstable angina). The model is based on parameters registered at admission and further calculation of death risk during in-hospital follow-up period. This predicted risk gives a chance to divide patients into risk groups - with minimal (lethality <1 %) to maximal (lethality >40 %) risk. This highly effective technology provides reproducible prognostic results.

During regional population family survey, 1298 of Rostov-on-Don City and Region citizens were examined. Mean age was 42, 61 ± 0, 58 years. There were 527 men and 771 women; total number of families surveyed was 270. Correlation and regression analyses, as well as special population-level genetic analysis methods, were used. Prognostic models were developed in two- and multivariate regression analysis, with regression equation construction. Multiple regression equations, predicting systolic and diastolic blood pressure levels, could be used in medico-genetic counseling and population screening programs, to identify arterial hypertension high-risk groups.

In 125 females with arterial hypertension (AH) and 30 females with normal blood pressure (BP), from reproductive-age group (29-46years), cardiovascular disease (CVD) risk factor prevalence was investigated. In AH patients, comparing to normotensive females, such CVD risk factor as salt consumption, gestosis in anamnesis, CVD in family history (FH) were more prevalent. In examined cohort, BP level significantly correlated with age and AH duration, anthropometry parameters and total cholesterol level. Significant AH predictors (p<0. 05) were AH duration, gestosis in anamnesis, AH in FH, and waist to hips circumference ratio. In reproductive-age women, active prevention of gestosis, that plays a role in AH pathogenesis, is necessary.

The article is devoted to body weight (BW) influence on cardiovascular disease (CVD) prevalence in climacteric women. The case-control study included 849 women. Group I included 283 females with normal BW, Group II - 283 overweight women, and Group III - 283 obese patients. Anthropometry, lipid and carbohydrate metabolism parameters, prevalence of arterial hypertension (AH), coronary heart disease (CHD)), chronic heart failure (CHF), myocardial infarction (MI), acute cerebrovascular events, and carbohydrate metabolism disturbances were examined. In Groups II and III, prevalence of AH was 65 % and 85. 2 %; CHD) - 13. 4 % and 9. 9 %; CHF- 28. 3 % and 43. 5 %; carbohydrate metabolism disturbances - 2. 5 % and 12 %, respectively, that was significantly greater than in women with normal BW: 53 %, 7. 1 %, 21. 3 %, and 2. 1 %, respectively. No increase in acute cerebrovascular event or MI prevalence was registered in Group III. Therefore, AH, CHD, and CHF prevalence in climacteric women was increased among overweight and obese individuals.

The author discusses issues of arterial hypertension terminology and classification use in everyday clinical practice.

The review is devoted to systemic thrombolysis in patients with acute myocardial infarction, as one of the most accessible reperfusion methods. The link between post-thrombolysis infarct-related artery status and future coronary heart disease progression is emphasized. Post-thrombolysis treatment strategy is discussed. Aggressive tactics in patients with recurrent coronary circulation disturbances improves clinical outcomes.